United Therapeutics Corporation (UTHR) Return on Assets (ROA): 19.17%
Is United Therapeutics Corporation’s return on assets (ROA) high or low?
United Therapeutics Corporation's return on assets (ROA) of 19.17% is 45% above its 5-year average of 13.22%, near the high end of its 5-year range (9.20%–19.17%).
As of Saturday, June 13, 2026. 15.59% above its 12-month average of 16.59%.
UTHR Return on Assets (ROA) Chart
UTHR Average Return on Assets (ROA) Chart
UTHR Current vs Average Return on Assets (ROA) Chart
UTHR Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
19.17%
RETURN ON ASSETS (ROA) AVG TTM
16.59%
RETURN ON ASSETS (ROA) AVG 3Y
14.73%
RETURN ON ASSETS (ROA) AVG 5Y
13.22%
RETURN ON ASSETS (ROA) AVG 10Y
15.36%
RETURN ON ASSETS (ROA) AVG 15Y
14.74%
RETURN ON ASSETS (ROA) AVG 20Y
13.04%
CURRENT VS TTM AVG
+15.59%
CURRENT VS 3Y AVG
+30.10%
CURRENT VS 5Y AVG
+45.06%
CURRENT VS 10Y AVG
+24.80%
CURRENT VS 15Y AVG
+30.05%
CURRENT VS 20Y AVG
+46.96%
UTHR Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| United Therapeutics Corporation (UTHR) | $23.17B | 19.17% | 16.59% | 14.73% | 13.22% |
| Waters Corporation (WAT) | $23.17B | 1.83% | 13.34% | 15.53% | 17.15% |
| BioNTech SE (BNTX) | $22.90B | -6.03% | -3.96% | 9.16% | 17.06% |
| Mettler-Toledo International Inc. (MTD) | $22.86B | 23.85% | 25.02% | 24.63% | 23.85% |
| Labcorp Holdings Inc. (LH) | $21.83B | 4.93% | 4.41% | 4.42% | 6.18% |
| Veeva Systems Inc. (VEEV) | $25.92B | 10.31% | 9.93% | 9.72% | 10.43% |
| Moderna, Inc. (MRNA) | $19.80B | -27.80% | -24.02% | -10.32% | -0.33% |
| DexCom, Inc. (DXCM) | $29.08B | 14.03% | 11.04% | 9.26% | 8.83% |
| Hologic, Inc. (HOLX) | $16.97B | 5.92% | 7.45% | 8.56% | 11.79% |
| Biogen Inc. (BIIB) | $29.53B | 4.65% | 5.11% | 6.74% | 8.29% |
Asset Efficiency
ROA
19.2%
ROE
21.8%
United Therapeutics Corporation Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
United Therapeutics Corporation Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for United Therapeutics Corporation (UTHR)?
- The return on assets (ROA) for UTHR stock is 19.17%.
- Is United Therapeutics Corporation's return on assets (ROA) high or low?
- United Therapeutics Corporation's return on assets (ROA) of 19.17% is 45% above its 5-year average of 13.22%, near the high end of its 5-year range (9.20%–19.17%).
- What is the TTM average return on assets (ROA) for United Therapeutics Corporation (UTHR)?
- The TTM average return on assets (ROA) for UTHR stock is 16.59%.
- What is the 3Y average return on assets (ROA) for United Therapeutics Corporation (UTHR)?
- The 3Y average return on assets (ROA) for UTHR stock is 14.73%.
- What is the 5Y average return on assets (ROA) for United Therapeutics Corporation (UTHR)?
- The 5Y average return on assets (ROA) for UTHR stock is 13.22%.
- What is the 10Y average return on assets (ROA) for United Therapeutics Corporation (UTHR)?
- The 10Y average return on assets (ROA) for UTHR stock is 15.36%.
- What is the 15Y average return on assets (ROA) for United Therapeutics Corporation (UTHR)?
- The 15Y average return on assets (ROA) for UTHR stock is 14.74%.
- What is the 20Y average return on assets (ROA) for United Therapeutics Corporation (UTHR)?
- The 20Y average return on assets (ROA) for UTHR stock is 13.04%.
United Therapeutics Corporation Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 16.94% |
| 2024-12-31 | 16.23% |
| 2023-12-31 | 13.74% |
| 2022-12-31 | 12.03% |
| 2021-12-31 | 9.20% |
| 2020-12-31 | 11.15% |
| 2019-12-31 | -2.67% |
| 2018-12-31 | 17.32% |
| 2017-12-31 | 14.51% |
| 2016-12-31 | 30.69% |
| 2015-12-31 | 29.83% |
| 2014-12-31 | 18.05% |
| 2013-12-31 | 8.36% |
| 2012-12-31 | 18.72% |
| 2011-12-31 | 14.35% |
| 2010-12-31 | 7.40% |
| 2009-12-31 | 1.85% |
| 2008-12-31 | -4.91% |
| 2007-12-31 | 3.38% |
| 2006-12-31 | 15.46% |
| 2005-12-31 | 22.31% |
| 2004-12-31 | 7.46% |
| 2003-12-31 | -5.55% |
| 2002-12-31 | -12.81% |
| 2001-12-31 | -17.58% |
| 2000-12-31 | -30.17% |
| 1999-12-31 | -55.93% |
| 1998-12-31 | -68.45% |
Related Metrics
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martine A. Rothblatt